Atopic Dermatitis
📧 Sign up to get email alerts when something new happens for Atopic Dermatitis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-18EMA Authorised: Dupixent (dupilumab) — Sanofi Winthrop Industrie
The EMA has authorised Dupixent (dupilumab) for multiple indications including atopic dermatitis, prurigo, esophageal diseases, asthma, and …
-
EMA approval · 2026-08-06EMA Authorised: Cibinqo (abrocitinib) — Pfizer Europe MA EEIG
EMA confirms authorisation of Cibinqo (abrocitinib) for atopic dermatitis in Europe.
-
EMA approval · 2026-08-03EMA Authorised: Opzelura (ruxolitinib phosphate) — Incyte Biosciences Distribution B.V.
EMA has authorised Opzelura (ruxolitinib phosphate) for use in vitiligo and atopic dermatitis, with Incyte Biosciences Distribution B.V. as …
-
EMA approval · 2026-07-17EMA Authorised: Anzupgo (Delgocitinib) — LEO Pharma A/S
Anzupgo (delgocitinib) has been authorised by the EMA for dermatitis/eczema with LEO Pharma A/S as the marketing authorization holder.
-
EMA approval · 2026-07-15EMA Authorised: Rinvoq (upadacitinib) — AbbVie Deutschland GmbH & Co. KG
Rinvoq (upadacitinib) has been authorised by the EMA for multiple inflammatory diseases including rheumatoid arthritis, psoriatic arthritis,…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-04-20EMA Authorised: Dupixent (dupilumab) — Sanofi Winthrop Industrie
The EMA authorised Dupixent (dupilumab) for multiple EU indications, including atopic dermatitis, prurigo nodularis, eosinophilic esophagiti…
-
EMA approval · 2026-04-07EMA Authorised: Adtralza (tralokinumab) — LEO Pharma A/S
The EMA authorised Adtralza (tralokinumab) by LEO Pharma A/S for atopic dermatitis in the European Union. Decision date: 26 March 2026.
-
EMA approval · 2026-03-20EMA Authorised: Ebglyss (Lebrikizumab) — Almirall, S.A.
EMA authorised Ebglyss (Lebrikizumab) for atopic dermatitis, with Almirall, S.A. as the marketing authorisation holder. Decision date: 14 Ja…
-
EMA approval · 2026-03-02EMA Authorised: Nemluvio (nemolizumab) — Galderma International
The European Medicines Agency has authorised nemolizumab (Nemluvio) for use in atopic dermatitis and prurigo, marking a new monoclonal antib…
-
FDA approval · 2026-02-12FDA Approved: DIFAMILAST — Original Application (Acrotech Biopharma Inc)
FDA approved the original application for Difamilast (ADQUEY) from Acrotech Biopharma Inc. for the treatment of atopic dermatitis.
-
EMA approval · 2026-02-06EMA Authorised: Cibinqo (abrocitinib) — Pfizer Europe MA EEIG
The European Medicines Agency authorised Cibinqo (abrocitinib) for atopic dermatitis, with Pfizer Europe MA EEIG as the marketing authorizat…
-
FDA approval · 2025-12-17FDA Approved: ADBRY — Supplemental Application (LEO Pharma Inc.)
The FDA approved a supplemental application for ADBRY (tralokinumab-ldrm) submitted by LEO Pharma Inc.
-
FDA approval · 2025-12-16FDA Approved: BECLOMETHASONE DIPROPIONATE — Original Application (Amneal Pharmaceuticals NY LLC)
The FDA approved Amneal Pharmaceuticals NY LLC's Beclomethasone Dipropionate as an original-application generic medication, a topical cortic…
-
EMA approval · 2025-12-09EMA Authorised: Anzupgo (Delgocitinib) — LEO Pharma A/S
The European Medicines Agency authorised Anzupgo (delgocitinib) by LEO Pharma A/S for dermatitis and eczema in the EU.
-
EMA approval · 2025-12-03EMA Authorised: Protopic (tacrolimus) — LEO Pharma A/S
The European Medicines Agency has authorised Protopic (tacrolimus) by LEO Pharma A/S for the treatment of atopic dermatitis.
-
FDA approval · 2025-09-16FDA Approved: FLUOCINOLONE ACETONIDE OIL — Supplemental Application (RISING PHARMA HOLDINGS, INC.)
FDA approved a supplemental application to add Fluocinolone Acetonide Oil as an approved topical formulation of fluocinolone acetonide by Ri…
-
FDA approval · 2025-07-18FDA Approved: FLUOCINOLONE ACETONIDE OIL — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for Fluocinonide Acetonide Oil, a topical corticosteroid product from Rising Pharma Holdings, In…
-
FDA approval · 2025-04-11FDA Approved: TRIAMCINOLONE ACETONIDE — Original Application (Dr. Reddy's Laboratories Inc)
The FDA approved Dr. Reddy's Laboratories' Triamcinolone Acetonide as an original application (generic) for topical use, adding a generic co…
-
FDA approval · 2025-03-26FDA Approved: RINVOQ — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for Rinvoq (upadacitinib) from AbbVie, resulting in labeling changes to the product.
-
FDA approval · 2025-02-26FDA Approved: FLUOCINONIDE — Original Application (QUAGEN PHARMACEUTICALS LLC)
FDA approved fluocinonide from Quagen Pharmaceuticals LLC under an Original Application (ANDA 216389). This is a generic topical corticoster…
-
FDA approval · 2025-02-13FDA Approved: PREDNISOLONE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental Abbreviated New Drug Application for a generic prednisolone product from PAI Holdings/PAI Pharma, signaling regu…
-
FDA approval · 2024-12-09FDA Approved: TRIAMCINOLONE ACETONIDE — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approval of Hikma's generic Triamcinolone Acetonide (ANDA 215254) as an original-application topical corticosteroid product for dermatol…
-
FDA approval · 2024-11-25FDA Approved: HYDROCORTISONE — Original Application (Eywa Pharma Inc)
FDA approved HYDROCORTISONE from Eywa Pharma Inc under an Original Application (ANDA 217160). This entry documents the approval of a generic…
-
FDA approval · 2024-09-12FDA Approved: DUPIXENT — Supplemental Application (sanofi-aventis U.S. LLC)
FDA approved a supplemental application for Dupixent (dupilumab) submitted by sanofi-aventis U.S. LLC.
-
FDA approval · 2024-08-22FDA Approved: BETAMETHASONE VALERATE — Original Application (Alembic Pharmaceuticals Limited)
FDA approved an original ANDA for Betamethasone Valerate topical (Alembic Pharmaceuticals), a generic corticosteroid product for inflammator…